Description

Elocalcitol is a synthetic, non-hypercalcemic vitamin D receptor agonist (VDRA) with significant therapeutic potential. Its primary value lies in its selective action, offering targeted biological effects without the undesirable side effects, such as hypercalcemia, associated with other vitamin D analogs. This compound is of critical interest to pharmaceutical research and development teams focused on metabolic and proliferative disorders. Elocalcitol CAS NO 199798-84-0 represents a key advanced intermediate for developing novel treatments in areas like oncology and urology.

Application

• Pharmaceutical Active Ingredient (API): Serves as the core active component in the development of prescription medications.
• Oncology Research: Investigated for its antiproliferative and differentiating effects in various cancer cell lines and preclinical models.
• Metabolic Disorder Therapeutics: A key candidate for research into conditions like secondary hyperparathyroidism and chronic kidney disease-mineral and bone disorder (CKD-MBD).
• Urological Applications: Studied for potential benefits in benign prostatic hyperplasia (BPH) and related urological conditions.
• Biochemical Research: Used as a high-purity reference standard and probe in studies of vitamin D receptor (VDR) signaling pathways.
• Preclinical & Clinical Development: Employed in formulation studies, pharmacokinetic/pharmacodynamic (PK/PD) modeling, and clinical trial material (CTM) manufacturing.

Basic Information

Product Name	Elocalcitol
CAS No.	199798-84-0
Molecular Formula	C₂₇H₄₄O₃
Molecular Weight	416.64 g/mol
Synonyms	BXL-628; (1R,3S)-5-[(2Z)-2-[(1R,3aS,7aR)-1-[(1R,2E)-4-Cyclopropyl-1-hydroxy-4-methyl-2-penten-1-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol; 1α,24(S)-Dihydroxy-22,23-didehydro-20-epi-vitamin D₃ / 20-epi-22,23-didehydro-1α,24(S)-dihydroxyvitamin D₃; Ro-26-9228
EINECS	Contact for details

Quality Control

Our Elocalcitol is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity, chiral purity determination, and identification by spectroscopic methods (NMR, IR, MS), to ensure it meets stringent specifications for pharmaceutical research. Certificates of Analysis (COA) detailing all test results are provided with every shipment. We can support development with materials aligned with ICH Q7 and current Good Manufacturing Practice (cGMP) principles for advanced intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store under an inert atmosphere (e.g., nitrogen or argon) at controlled room temperature (15-25°C) or as specified on the label or CoA. The material is light-sensitive and easily oxidized; prolonged exposure to air or light should be avoided to maintain stability and purity.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Purity (HPLC)	≥ 98.0%
Chiral Purity	≥ 99.0%
Related Substances (HPLC)	Individual impurity ≤ 0.5%; Total impurities ≤ 2.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Water Content (KF)	≤ 0.5% w/w

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.